Şükrü Ulusoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Şükrü Ulusoy has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
Gulsum Ozkan
Department of Nephrology, Hatay Antakya State Hospital, Hatay
9 shared publications- Gülsüm Özkan
Department of Nephrology, Tekirdağ Namık Kemal University, School of Medicine, Tekirdağ, Turkey
7 shared publications Adnan Yavuz
Trabzon RNS Hemodialysis Center, Trabzon, Turkey
4 shared publications- Beyhan Güvercin
Karadeniz Teknik Üniversitesi
4 shared publications - Kubra Kaynar
Department of Nephrology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
4 shared publications - Yunus Erdem
Hacettepe University
4 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 13 (10) , 333-335
Pauci-Immune crescentic glomerulonephritis in a patient initially considered to have diabetic kidney disease
Dear Editor, Diabetes mellitus is one of the leading causes of chronic kidney disease and end-stage kidney disease worldwide. In clinical practice, diabetic kidney disease is usually diagnosed based on the duration of diabetes, albuminuria, associated microvascular complications, and the trajectory of kidney function. However, kidney disease in a patient with diabetes is not necessarily attributable to diabetes, and an atypical clinical course should prompt consideration of an alternative diagnosis. We report a patient initially considered to have diabetic kidney disease in whom kidney biopsy demonstrated pauci-immune crescentic glomerulonephritis (PIGN). A 36-year-old man with a 22-year history of type 2 diabetes mellitus, 9 years of hypertension, and approximately 1 year of chronic kidney disease had been followed at another center. His known baseline serum creatinine was 1.2 mg/dL, and diabetic retinopathy was present. He was hospitalized elsewhere because of acute kidney injury and was referred to our center for consideration of kidney biopsy after 24-hour urinary protein excretion of 3 g/day was detected. At presentation, bilateral pretibial edema, proteinuria, and acute kidney injury were present. The admission serum creatinine was 8.44 mg/dL, blood urea nitrogen was 56 mg/dL, and estimated glomerular filtration rate was 8 mL/min/1.73 m² . Renal replacement therapy was initiated because of uremic symptoms. The patient had undergone metabolic surgery in 2021, and HbA1c during hospitalization was 5.6%. On follow-up, 24-hour urinary protein excretion was 5.8 g/day, albumin excretion was 3.1 g/day, and creatinine clearance was 2.35 mL/min. Serologic testing for anti-PLA2R, antinuclear antibodies, Antı MPO and PR3 ANCA, anti-GBM antibodies, anti-dsDNA, and ENA was negative. C3, C4, and immunoglobulin levels were normal, and serum protein electrophoresis showed no monoclonal band. Urinary RBC count was elevated at 109; however, the sediment remained inactive, with no RBC casts. Although the long-standing diabetes, diabetic retinopathy, proteinuria, and clinical background initially supported diabetic kidney disease, the abrupt and severe decline in kidney function was atypical. Kidney biopsy was therefore performed to clarify the cause of acute kidney injury. Nineteen glomeruli were evaluated. 10 glomeruli are globally sclerotic. Out of the 9 non-sclerotic glomeruli, 7 show a cellular-fibrocellular crescentic morphology. Fibrinoid necrosis is present in 2 glomeruli. Segmental increase in basement membrane rigidity, mild mesangial matrix and cellular increase, and occasional polymorphonuclear leukocyte infiltration are observed in 2 glomeruli. The interstitium shows increased fibrosis involving 30% of the examined cortical area, along with patchy mononuclear inflammatory cell infiltration. The represented vascular structures show subintimal fibrosis that disproportionately narrows the lumen for the patient's age, fibrinoid necrosis of the vessel wall, and adventitial arteritis. No immunofluorescence staining was detected in renal biopsy specimen (Figures A and B). Electron microscopy could not be performed. The findings were considered consistent with pauci-immune crescentic glomerulonephritis Following informed consent, the patient received intravenous pulse methylprednisolone therapy and a single dose of cyclophosphamide. However, renal function did not recover sufficiently to discontinue renal replacement therapy, and the patient remained dialysis-dependent during approximately two months of follow-up. In view of the persistent dialysis dependence and lack of renal recovery, corticosteroid therapy was gradually tapered and discontinued, and no further cyclophosphamide was administered. This case illustrates the diagnostic risk of attributing kidney dysfunction in a patient with long-standing diabetes solely to diabetic kidney disease. The presence of diabetic retinopathy and substantial proteinuria made diabetic kidney disease clinically plausible; however, the rapid loss of kidney function, very low creatinine clearance, oligoanuria, and requirement for renal replacement therapy were not compatible with the expected slowly progressive course. Kidney biopsy established a different diagnosis and directly changed the treatment strategy. Pauci-immune crescentic glomerulonephritis is an important cause of rapidly progressive glomerulonephritis and may lead to irreversible kidney failure when diagnosis is delayed. Notably, ANCA was negative in our patient. Thus, negative serologic testing does not exclude pauci-immune crescentic glomerulonephritis and should not preclude kidney biopsy when the clinical course is atypical or rapidly progressive. In patients with diabetes, a rapid increase in serum creatinine, oligoanuria, nephrotic-range proteinuria, or another unexpected clinical trajectory should raise suspicion for non-diabetic kidney disease. This case emphasizes the central role of kidney biopsy in establishing the correct diagnosis and guiding disease-specific treatment in such patients.
- 23 October 2026
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 13 (10) , 333-335
Open AccessPauci-Immune crescentic glomerulonephritis in a patient initially considered to have diabetic kidney disease
Dear Editor, Diabetes mellitus is one of the leading causes of chronic kidney disease and end-stage kidney disease worldwide. In clinical practice, diabetic kidney disease is usually diagnosed based on the duration of diabetes, albuminuria, associated microvascular complications, and the trajectory of kidney function. However, kidney disease in a patient with diabetes is not necessarily attributable to diabetes, and an atypical clinical course should prompt consideration of an alternative diagnosis. We report a patient initially considered to have diabetic kidney disease in whom kidney biopsy demonstrated pauci-immune crescentic glomerulonephritis (PIGN). A 36-year-old man with a 22-year history of type 2 diabetes mellitus, 9 years of hypertension, and approximately 1 year of chronic kidney disease had been followed at another center. His known baseline serum creatinine was 1.2 mg/dL, and diabetic retinopathy was present. He was hospitalized elsewhere because of acute kidney injury and was referred to our center for consideration of kidney biopsy after 24-hour urinary protein excretion of 3 g/day was detected. At presentation, bilateral pretibial edema, proteinuria, and acute kidney injury were present. The admission serum creatinine was 8.44 mg/dL, blood urea nitrogen was 56 mg/dL, and estimated glomerular filtration rate was 8 mL/min/1.73 m² . Renal replacement therapy was initiated because of uremic symptoms. The patient had undergone metabolic surgery in 2021, and HbA1c during hospitalization was 5.6%. On follow-up, 24-hour urinary protein excretion was 5.8 g/day, albumin excretion was 3.1 g/day, and creatinine clearance was 2.35 mL/min. Serologic testing for anti-PLA2R, antinuclear antibodies, Antı MPO and PR3 ANCA, anti-GBM antibodies, anti-dsDNA, and ENA was negative. C3, C4, and immunoglobulin levels were normal, and serum protein electrophoresis showed no monoclonal band. Urinary RBC count was elevated at 109; however, the sediment remained inactive, with no RBC casts. Although the long-standing diabetes, diabetic retinopathy, proteinuria, and clinical background initially supported diabetic kidney disease, the abrupt and severe decline in kidney function was atypical. Kidney biopsy was therefore performed to clarify the cause of acute kidney injury. Nineteen glomeruli were evaluated. 10 glomeruli are globally sclerotic. Out of the 9 non-sclerotic glomeruli, 7 show a cellular-fibrocellular crescentic morphology. Fibrinoid necrosis is present in 2 glomeruli. Segmental increase in basement membrane rigidity, mild mesangial matrix and cellular increase, and occasional polymorphonuclear leukocyte infiltration are observed in 2 glomeruli. The interstitium shows increased fibrosis involving 30% of the examined cortical area, along with patchy mononuclear inflammatory cell infiltration. The represented vascular structures show subintimal fibrosis that disproportionately narrows the lumen for the patient's age, fibrinoid necrosis of the vessel wall, and adventitial arteritis. No immunofluorescence staining was detected in renal biopsy specimen (Figures A and B). Electron microscopy could not be performed. The findings were considered consistent with pauci-immune crescentic glomerulonephritis Following informed consent, the patient received intravenous pulse methylprednisolone therapy and a single dose of cyclophosphamide. However, renal function did not recover sufficiently to discontinue renal replacement therapy, and the patient remained dialysis-dependent during approximately two months of follow-up. In view of the persistent dialysis dependence and lack of renal recovery, corticosteroid therapy was gradually tapered and discontinued, and no further cyclophosphamide was administered. This case illustrates the diagnostic risk of attributing kidney dysfunction in a patient with long-standing diabetes solely to diabetic kidney disease. The presence of diabetic retinopathy and substantial proteinuria made diabetic kidney disease clinically plausible; however, the rapid loss of kidney function, very low creatinine clearance, oligoanuria, and requirement for renal replacement therapy were not compatible with the expected slowly progressive course. Kidney biopsy established a different diagnosis and directly changed the treatment strategy. Pauci-immune crescentic glomerulonephritis is an important cause of rapidly progressive glomerulonephritis and may lead to irreversible kidney failure when diagnosis is delayed. Notably, ANCA was negative in our patient. Thus, negative serologic testing does not exclude pauci-immune crescentic glomerulonephritis and should not preclude kidney biopsy when the clinical course is atypical or rapidly progressive. In patients with diabetes, a rapid increase in serum creatinine, oligoanuria, nephrotic-range proteinuria, or another unexpected clinical trajectory should raise suspicion for non-diabetic kidney disease. This case emphasizes the central role of kidney biopsy in establishing the correct diagnosis and guiding disease-specific treatment in such patients.
- 24 August 2026
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 40 (10) , 824-830
From guidelines to practice: antihypertensive prescribing preferences in Türkiye—the APP-Türkiye study
Antihypertensive prescribing patterns vary across countries, potentially influencing BP control rates, which remain suboptimal worldwide. To date, no study has evaluated national antihypertensive prescription distributions in Türkiye. This study aimed to investigate antihypertensive prescription preferences using nationwide health data. Data on age and sex were obtained for patients diagnosed with hypertension (HT) based on International Classification of Diseases-10 (ICD-10) codes and who were prescribed at least one antihypertensive drug between January 1, 2023, and January 1, 2024. Comorbidities were also identified using ICD-10 codes. Antihypertensive treatments were classified according to the Anatomical Therapeutic Chemical system. This study investigated the antihypertensive prescriptions of 10 705 115 individuals aged over 18. A total of 19 869 235 antihypertensives were prescribed over the one-year study period, with a mean number of 2.67 ± 1.53 per patient. The three most frequently prescribed antihypertensive groups in the general population were angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and their combinations, and beta blockers (BBs). Although the top three antihypertensive agents used across all age groups were similar to those in the general population, an increase in the prescription of BBs, diuretics, and calcium channel blockers was observed with advancing age. Antihypertensive preferences in cases with comorbid diseases were consistent with current guidelines, and the use of single-pill combinations was higher than that of monotherapy, at 54.96%. In the light of the national data, it may be concluded that Turkish physicians generally adhere to current hypertension guideline recommendations in their antihypertensive prescription preferences.
- 24 August 2026
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 40 (10) , 824-830
From guidelines to practice: antihypertensive prescribing preferences in Türkiye—the APP-Türkiye study
Antihypertensive prescribing patterns vary across countries, potentially influencing BP control rates, which remain suboptimal worldwide. To date, no study has evaluated national antihypertensive prescription distributions in Türkiye. This study aimed to investigate antihypertensive prescription preferences using nationwide health data. Data on age and sex were obtained for patients diagnosed with hypertension (HT) based on International Classification of Diseases-10 (ICD-10) codes and who were prescribed at least one antihypertensive drug between January 1, 2023, and January 1, 2024. Comorbidities were also identified using ICD-10 codes. Antihypertensive treatments were classified according to the Anatomical Therapeutic Chemical system. This study investigated the antihypertensive prescriptions of 10 705 115 individuals aged over 18. A total of 19 869 235 antihypertensives were prescribed over the one-year study period, with a mean number of 2.67 ± 1.53 per patient. The three most frequently prescribed antihypertensive groups in the general population were angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and their combinations, and beta blockers (BBs). Although the top three antihypertensive agents used across all age groups were similar to those in the general population, an increase in the prescription of BBs, diuretics, and calcium channel blockers was observed with advancing age. Antihypertensive preferences in cases with comorbid diseases were consistent with current guidelines, and the use of single-pill combinations was higher than that of monotherapy, at 54.96%. In the light of the national data, it may be concluded that Turkish physicians generally adhere to current hypertension guideline recommendations in their antihypertensive prescription preferences.
- Open Access
- 30 March 2026
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 13 (3) , 45-50
Reset Osmostat in Chronic Hyponatremia: Physiology, Diagnosis, and Links to Congenital Midline Brain Malformations (with an illustrative case of Corpus Callosum Agenesis)
Objective: Reset osmostat (RO) is an under-recognized disorder of osmoregulation characterized by a downward resetting of the plasma osmolality threshold for arginine vasopressin release. Affected individuals develop chronic, typically mild and stable hypotonic hyponatremia while preserving the ability to dilute urine and excrete a water load. Because RO is frequently misclassified as the syndrome of inappropriate antidiuresis (SIAD), patients may undergo unnecessary investigations and receive potentially harmful therapies aimed at normalizing serum sodium. To summarize the physiology of the osmostat, identify clinical contexts associated with RO—including congenital midline brain malformations—and highlight practical diagnostic features that distinguish RO from SIAD and other causes of euvolemic hyponatremia. Material and Methods: This narrative review is based on targeted literature searches of PubMed and manual review of reference lists, with emphasis on osmoregulatory physiology, diagnostic strategies, and reported associations with congenital midline brain abnormalities. An illustrative case of chronic asymptomatic hyponatremia is also presented. Conclusions: RO represents a regulated but abnormally set osmoregulatory state in which vasopressin secretion occurs at a lower plasma osmolality threshold. Key diagnostic features include chronic, stable hyponatremia, preserved urinary dilution, normal fractional excretion of urate, and limited response to SIAD-directed therapies. RO has been reported in association with central nervous system disorders, particularly congenital midline malformations such as agenesis of the corpus callosum. Recognition of RO is essential to avoid misdiagnosis and inappropriate treatment. Management is typically conservative, with emphasis on avoiding unnecessary correction of serum sodium and preventing overly rapid correction when superimposed acute processes occur
- 30 March 2026
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 13 (3) , 45-50
Open AccessReset Osmostat in Chronic Hyponatremia: Physiology, Diagnosis, and Links to Congenital Midline Brain Malformations (with an illustrative case of Corpus Callosum Agenesis)
Objective: Reset osmostat (RO) is an under-recognized disorder of osmoregulation characterized by a downward resetting of the plasma osmolality threshold for arginine vasopressin release. Affected individuals develop chronic, typically mild and stable hypotonic hyponatremia while preserving the ability to dilute urine and excrete a water load. Because RO is frequently misclassified as the syndrome of inappropriate antidiuresis (SIAD), patients may undergo unnecessary investigations and receive potentially harmful therapies aimed at normalizing serum sodium. To summarize the physiology of the osmostat, identify clinical contexts associated with RO—including congenital midline brain malformations—and highlight practical diagnostic features that distinguish RO from SIAD and other causes of euvolemic hyponatremia. Material and Methods: This narrative review is based on targeted literature searches of PubMed and manual review of reference lists, with emphasis on osmoregulatory physiology, diagnostic strategies, and reported associations with congenital midline brain abnormalities. An illustrative case of chronic asymptomatic hyponatremia is also presented. Conclusions: RO represents a regulated but abnormally set osmoregulatory state in which vasopressin secretion occurs at a lower plasma osmolality threshold. Key diagnostic features include chronic, stable hyponatremia, preserved urinary dilution, normal fractional excretion of urate, and limited response to SIAD-directed therapies. RO has been reported in association with central nervous system disorders, particularly congenital midline malformations such as agenesis of the corpus callosum. Recognition of RO is essential to avoid misdiagnosis and inappropriate treatment. Management is typically conservative, with emphasis on avoiding unnecessary correction of serum sodium and preventing overly rapid correction when superimposed acute processes occur
- Open Access
- 28 May 2025
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 12 (5) , 186-188
Beyond the Teeth: Amelogenesis Imperfecta as a Marker of Systemic Disease
Objective: Amelogenesis Imperfecta (AI) is a genetic disorder affecting enamel formation, with a prevalence ranging from 1:700 to 1:15,000. The hypoplastic type of AI, in particular, may be associated with ectodermal syndromes and metabolic disorders. The co-occurrence of enamel hypoplasia and nephrocalcinosis was first described in 1972. Nephrocalcinosis, characterized by calcium salt deposition in the renal parenchyma, may be asymptomatic or lead to renal impairment. Randall’s plaques, representing early-stage calcification at the renal papillae, play a key role in the pathogenesis of nephrolithiasis. Case: We present a 21-year-old female with yellow-brown discoloration of the enamel, diagnosed with hypoplastic AI. Further evaluation revealed nephrocalcinosis and Randall’s plaques, despite normal renal function. Her bone mineral density was also reduced. Genetic testing and endocrine assessment were initiated. Potassium citrate therapy was commenced to prevent stone formation. Conclusion: This case underscores the potential of AI to serve as an early clinical marker of systemic disease. A multidisciplinary approach can reveal otherwise silent but clinically significant comorbidities.
- 28 May 2025
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 12 (5) , 186-188
Open AccessBeyond the Teeth: Amelogenesis Imperfecta as a Marker of Systemic Disease
Objective: Amelogenesis Imperfecta (AI) is a genetic disorder affecting enamel formation, with a prevalence ranging from 1:700 to 1:15,000. The hypoplastic type of AI, in particular, may be associated with ectodermal syndromes and metabolic disorders. The co-occurrence of enamel hypoplasia and nephrocalcinosis was first described in 1972. Nephrocalcinosis, characterized by calcium salt deposition in the renal parenchyma, may be asymptomatic or lead to renal impairment. Randall’s plaques, representing early-stage calcification at the renal papillae, play a key role in the pathogenesis of nephrolithiasis. Case: We present a 21-year-old female with yellow-brown discoloration of the enamel, diagnosed with hypoplastic AI. Further evaluation revealed nephrocalcinosis and Randall’s plaques, despite normal renal function. Her bone mineral density was also reduced. Genetic testing and endocrine assessment were initiated. Potassium citrate therapy was commenced to prevent stone formation. Conclusion: This case underscores the potential of AI to serve as an early clinical marker of systemic disease. A multidisciplinary approach can reveal otherwise silent but clinically significant comorbidities.
- Open Access
- 22 April 2024
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 26 (6) , 708-713
How many blood pressure measurements should we take in the office?
No consensus has emerged among different guidelines concerning how many blood pressure (BP) measurements should be performed at office visits in the diagnosis of hypertension. The purpose of this study was to examine the compatibility of various multiple average office BP measurements and 24‐h BP monitoring (ABPM) in patients followed up in the posthoc analysis of the Cappadocia hypertension cohort. A total 1158 office BP measurements by 207 patients were examined. The results were then classified as G1 (average of the 1st and 2nd BP), G2 (average of the 2nd and 3rd), G3 (average of the 2nd, 3rd, and 4th), G4 (average of the 2nd, 3rd, 4th, and 5th), and G5 (average of all five measurements). Compatibility between the average values in the groups and concomitant 24‐h ABPM data was examined. While a significant difference was observed between daytime 24‐h ABPM SBP and G1 (p = .002), no difference was found in the other groups. Office DBP approached the daytime 24‐h ABPM values as the number of measurements in the five groups increased, although average office DBP data in all groups were higher than daytime 24‐h ABPM DBP (p = .000 for all). In light of our study results, we recommend that three office BP measurements be performed and that the average of the 2nd and 3rd measurements be used for SBP, while in terms of DBP, we recommend that as many measurements as possible be taken without the 1st value being included in the average.
- 22 April 2024
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 26 (6) , 708-713
Open AccessHow many blood pressure measurements should we take in the office?
No consensus has emerged among different guidelines concerning how many blood pressure (BP) measurements should be performed at office visits in the diagnosis of hypertension. The purpose of this study was to examine the compatibility of various multiple average office BP measurements and 24‐h BP monitoring (ABPM) in patients followed up in the posthoc analysis of the Cappadocia hypertension cohort. A total 1158 office BP measurements by 207 patients were examined. The results were then classified as G1 (average of the 1st and 2nd BP), G2 (average of the 2nd and 3rd), G3 (average of the 2nd, 3rd, and 4th), G4 (average of the 2nd, 3rd, 4th, and 5th), and G5 (average of all five measurements). Compatibility between the average values in the groups and concomitant 24‐h ABPM data was examined. While a significant difference was observed between daytime 24‐h ABPM SBP and G1 (p = .002), no difference was found in the other groups. Office DBP approached the daytime 24‐h ABPM values as the number of measurements in the five groups increased, although average office DBP data in all groups were higher than daytime 24‐h ABPM DBP (p = .000 for all). In light of our study results, we recommend that three office BP measurements be performed and that the average of the 2nd and 3rd measurements be used for SBP, while in terms of DBP, we recommend that as many measurements as possible be taken without the 1st value being included in the average.
- 3 November 2023
- Published by Istanbul University
- p. 89-97
Protei̇nüri̇si̇ Olan Yaşlı Hastaya Yaklaşım
- 5 May 2022
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 44 (6) , 502-506
The effect of hypertension and antihypertensive therapies on the course of COVID-19 infection: Turkish national health system data
The effect of hypertension (HT) and antihypertensive therapies such as renin-angiotensin-aldosterone system (RAAS) blockers on the disease course in COVID-19 patients is controversial. The purpose of this study was to evaluate the effect of HT and antihypertensive therapies on the course of COVID-19 disease. The age, sex, comorbid diseases, and antihypertensive therapies of 132,790 patients with positive COVID-19 real-time transcriptase polymerase chain reaction (RT-PCR) tests in the Turkish Health Ministry National COVID-19 database between 11 March and 31 May 2020, were examined and analyzed. Forty-one percent of the 132,790 patients in this study (median age: 40, 47.3% female) were hospitalized for treatment, and 4.5% were followed-up in the intensive care unit (ICU). The most frequent comorbid disease, at 19.5%, was HT (n = 25,863). Mortality was determined in 4.9% of HT patients and 1.9% of non-HT patients (p < .001). HT, age, and male gender emerged as independent predictors of hospitalization and admission to the ICU, while HT was not a predictor of mortality. In addition, no adverse effect of any antihypertensive treatment, including RAAS inhibitors, on mortality was detected. Based on Turkish national data, HT is common in COVID-19 patients, but does not appear to be an independent predictor of mortality, and no adverse effect of RAAS inhibitors on COVID-19-related mortality was observed.
- 5 May 2022
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 44 (6) , 502-506
The effect of hypertension and antihypertensive therapies on the course of COVID-19 infection: Turkish national health system data
The effect of hypertension (HT) and antihypertensive therapies such as renin-angiotensin-aldosterone system (RAAS) blockers on the disease course in COVID-19 patients is controversial. The purpose of this study was to evaluate the effect of HT and antihypertensive therapies on the course of COVID-19 disease. The age, sex, comorbid diseases, and antihypertensive therapies of 132,790 patients with positive COVID-19 real-time transcriptase polymerase chain reaction (RT-PCR) tests in the Turkish Health Ministry National COVID-19 database between 11 March and 31 May 2020, were examined and analyzed. Forty-one percent of the 132,790 patients in this study (median age: 40, 47.3% female) were hospitalized for treatment, and 4.5% were followed-up in the intensive care unit (ICU). The most frequent comorbid disease, at 19.5%, was HT (n = 25,863). Mortality was determined in 4.9% of HT patients and 1.9% of non-HT patients (p < .001). HT, age, and male gender emerged as independent predictors of hospitalization and admission to the ICU, while HT was not a predictor of mortality. In addition, no adverse effect of any antihypertensive treatment, including RAAS inhibitors, on mortality was detected. Based on Turkish national data, HT is common in COVID-19 patients, but does not appear to be an independent predictor of mortality, and no adverse effect of RAAS inhibitors on COVID-19-related mortality was observed.
- Open Access
- 1 November 2020
- Published by Elsevier in Nefrología (English Edition)
- Vol. 40 (6) , 681-682
Don’t forget syphilis in membranous nephropathy before immunosuppressants: Latent syphilis in a patient with proteinuria
- 1 November 2020
- Published by Elsevier in Nefrología (English Edition)
- Vol. 40 (6) , 681-682
Open AccessDon’t forget syphilis in membranous nephropathy before immunosuppressants: Latent syphilis in a patient with proteinuria
- Open Access
- 26 September 2019
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 21 (11) , 1724-1731
Down‐regulation of miRNA 145 and up‐regulation of miRNA 4516 may be associated with primary hypertension
Complex mechanisms including genetic factors have been proposed in the pathogenesis of primary hypertension (HT). Micro RNAs (miRNAs) are single‐stranded RNA molecules that are not converted into protein products. However, it has been established that genes regulate conversion into protein products. The primary aim of this study was to investigate the roles of miRNA 4516, miRNA 145, miRNA 24, and miRNA 181a in the pathogenesis of HT. The secondary aim was to investigate the relation between these miRNAs and renin, aldosterone, norepinephrine, renalase, and NOS. Fifty‐two hypertensive and 51 control normotensive individuals under observation in the Cappadocia cohort were included in the study. miRNA 4516, miRNA 181a, miRNA 24, and miRNA 145 levels were measured using the ddPCR method. miRNA 4516 and norepinephrine levels were significantly higher in the HT group (P < .005 for both), while miRNA 145 levels were significantly lower (<.05). miRNA 4516 up‐regulation (P < .05) and miRNA 145 down‐regulation (P < .05) were identified as independent predictors of HT. Renalase exhibited negative correlation with miRNA 4516 and positive correlation with miRNA 145 in the patient and control group. In addition, negative correlation was present between miRNA 24 and NE and NOS and between miRNA 181a and NOS in the patient group. Our study identified, for the first time in the literature, miRNA 4516 up‐regulation and miRNA 145 down‐regulation as independent determinants of HT. Further studies performed in the light of our findings may lead to a better understanding of the pathogenesis and new therapeutic possibilities.
- 26 September 2019
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 21 (11) , 1724-1731
Open AccessDown‐regulation of miRNA 145 and up‐regulation of miRNA 4516 may be associated with primary hypertension
Complex mechanisms including genetic factors have been proposed in the pathogenesis of primary hypertension (HT). Micro RNAs (miRNAs) are single‐stranded RNA molecules that are not converted into protein products. However, it has been established that genes regulate conversion into protein products. The primary aim of this study was to investigate the roles of miRNA 4516, miRNA 145, miRNA 24, and miRNA 181a in the pathogenesis of HT. The secondary aim was to investigate the relation between these miRNAs and renin, aldosterone, norepinephrine, renalase, and NOS. Fifty‐two hypertensive and 51 control normotensive individuals under observation in the Cappadocia cohort were included in the study. miRNA 4516, miRNA 181a, miRNA 24, and miRNA 145 levels were measured using the ddPCR method. miRNA 4516 and norepinephrine levels were significantly higher in the HT group (P < .005 for both), while miRNA 145 levels were significantly lower (<.05). miRNA 4516 up‐regulation (P < .05) and miRNA 145 down‐regulation (P < .05) were identified as independent predictors of HT. Renalase exhibited negative correlation with miRNA 4516 and positive correlation with miRNA 145 in the patient and control group. In addition, negative correlation was present between miRNA 24 and NE and NOS and between miRNA 181a and NOS in the patient group. Our study identified, for the first time in the literature, miRNA 4516 up‐regulation and miRNA 145 down‐regulation as independent determinants of HT. Further studies performed in the light of our findings may lead to a better understanding of the pathogenesis and new therapeutic possibilities.
- Open Access
- 19 March 2018
- Published by Springer Nature in Hypertension Research
- Vol. 41 (6) , 460-468
Home sphygmomanometers can help in the control of blood pressure: a nationwide field survey
Home blood pressure monitoring (HBPM), which integrates patients into their treatment program, is a self-management tool. The prevalence of home sphygmomanometer ownership and patient compliance with HBPM guidelines are not well known, especially in developing and underdeveloped countries. The aims of this study were to measure the prevalence of home sphygmomanometer ownership among hypertensive subjects through a nationwide field survey (PatenT2), to investigate the validation of sphygmomanometers and consistency of the user arm circumference and cuff size of the upper-arm device owned, as well as to compare blood pressure (BP) readings between hypertensive subjects who have or do not have a sphygmomanometer. Sample selection was based on a multistratified proportional sampling procedure to select a nationally representative sample of the adult population (n = 5437). Of 1650 hypertensive subjects, 332 (20.1%) owned a device, but the percentage of patients who owned a sphygmomanometer was 28.8% among patients who were aware of their hypertension (260/902). The usage of wrist devices and nonvalidated devices is common, and selection of an appropriate cuff size is ignored. Linear-regression analysis showed that owning a BP monitor is associated with decreases of 3.7 mmHg and 2.8 mmHg for systolic and diastolic BPs, respectively. Many patients do not own a sphygmomanometer. The decrease of systolic and diastolic BPs among BP monitor owners is a striking finding. The implementation of a hypertension care program consisting of sphygmomanometer reimbursement and training of patients in its use for HBPM might be cost-effective.
- 19 March 2018
- Published by Springer Nature in Hypertension Research
- Vol. 41 (6) , 460-468
Open AccessHome sphygmomanometers can help in the control of blood pressure: a nationwide field survey
Home blood pressure monitoring (HBPM), which integrates patients into their treatment program, is a self-management tool. The prevalence of home sphygmomanometer ownership and patient compliance with HBPM guidelines are not well known, especially in developing and underdeveloped countries. The aims of this study were to measure the prevalence of home sphygmomanometer ownership among hypertensive subjects through a nationwide field survey (PatenT2), to investigate the validation of sphygmomanometers and consistency of the user arm circumference and cuff size of the upper-arm device owned, as well as to compare blood pressure (BP) readings between hypertensive subjects who have or do not have a sphygmomanometer. Sample selection was based on a multistratified proportional sampling procedure to select a nationally representative sample of the adult population (n = 5437). Of 1650 hypertensive subjects, 332 (20.1%) owned a device, but the percentage of patients who owned a sphygmomanometer was 28.8% among patients who were aware of their hypertension (260/902). The usage of wrist devices and nonvalidated devices is common, and selection of an appropriate cuff size is ignored. Linear-regression analysis showed that owning a BP monitor is associated with decreases of 3.7 mmHg and 2.8 mmHg for systolic and diastolic BPs, respectively. Many patients do not own a sphygmomanometer. The decrease of systolic and diastolic BPs among BP monitor owners is a striking finding. The implementation of a hypertension care program consisting of sphygmomanometer reimbursement and training of patients in its use for HBPM might be cost-effective.